Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Company
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Number of employees : 1 941 people.
Sales per Business
2020
Immunotherapy Technologies549.84100%
USD in Million
Sales per region
20192020Delta
Germany121.54100%549.84100% +352.4%
USD in Million
Managers
Name Title Age Since
Ugur Sahin Chief Executive Officer 55 2008
Jens Holstein Chief Financial Officer 56 2021
Ízlem TŘreci Chief Medical Officer 53 2018
Sierk P÷tting Chief Operating Officer 47 2021
Sylke Maas, Dr. VP-Investor Relations & Business Strategy - -
Sean Marett Chief Business & Commercial Officer 55 2012
Ryan Richardson Chief Strategy Officer 53 2020
Members of the board
Name Title Age Since
Helmut Jeggle Chairman-Supervisory Board 50 2008
Christoph Huber, Dr. Member-Supervisory Board 76 2008
Michael Motschmann Member-Supervisory Board 63 2008
Ulrich Wandschneider, Dr. Member-Supervisory Board 60 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 246,310,081 214,949,219 87.3% 4,789,016 1.9% 87.3%
Shareholders
NameEquities%
PRIMECAP Management Co. 4,137,898 1.71%
Fidelity Management & Research Co. LLC 3,234,808 1.34%
Capital Research & Management Co. (World Investors) 2,972,225 1.23%
T. Rowe Price Associates, Inc. (Investment Management) 1,980,827 0.82%
BlackRock Fund Advisors 1,446,036 0.60%
Baillie Gifford & Co. 766,109 0.32%
Artisan Partners LP 704,954 0.29%
DJE Kapital AG 700,412 0.29%
Janus Capital Management LLC 635,977 0.26%
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 572,433 0.24%
Company contact information
BioNTech SE
An der Goldgrube 12
Mainz, Rheinland-Pfalz 55131

Phone : +49.6131.9084.0
Web : http://www.biontech.de
Brand Portfolio
In partnership withAllbrands.markets
More brands of BioNTech SE
Sector Bio Therapeutic Drugs